<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01012414</url>
  </required_header>
  <id_info>
    <org_study_id>09C.110</org_study_id>
    <nct_id>NCT01012414</nct_id>
  </id_info>
  <brief_title>Effect of Vitamin D Supplement on Inflammation Markers in High-Risk Cardiovascular Patients With Chronic Kidney Disease</brief_title>
  <acronym>VINCA-CKD</acronym>
  <official_title>The Effect of Vitamin D Supplementation on Markers of Inflammation in High-Risk Cardiovascular Patients With Low Levels of Serum 25-Hydroxyvitamin D</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if vitamin D supplementation changes the results of
      certain tests associated with inflammation in the body using an oral, synthetic form of
      vitamin D called paricalcitol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vitamin D deficiency is common and has been associated with an increased risk of heart
      disease. In patients with the combination of kidney disease and heart disease, inflammation
      is thought to contribute to a high rate of cardiac events. Less is known about the effects of
      vitamin D supplementation on certain tests associated with inflammation in the body.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Futility in enrollment as of May 31, 2011
  </why_stopped>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in High Sensitivity-C Reactive Protein (Serum)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Markers of Inflammation Including Interleukin (IL)-1, IL-6, Tumor Necrosis Factor Alpha, Matrix Metalloproteinase (MMP) -9 and Serum Amyloid A</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on Known Coronary Artery Disease Risk Factors Including Lipids and Blood Pressure.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on Carotid Intima-media Thickening (CIMT)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Chronic Kidney Disease</condition>
  <condition>Hypovitaminosis D</condition>
  <condition>Secondary Hyperparathyroidism</condition>
  <arm_group>
    <arm_group_label>oral paricalcitol 2 mcg daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral paricalcitol 2 mcg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>one oral placebo drug daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paricalcitol</intervention_name>
    <description>2 mcg oral paricalcitol daily</description>
    <arm_group_label>oral paricalcitol 2 mcg daily</arm_group_label>
    <other_name>Zemplar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and non-pregnant, non-lactating women greater than 18 years of age

          -  Able to given informed consent and complete scheduled visits

          -  History of established coronary artery disease (CAD)as defined by coronary stenosis in
             one or more vessels greater than or equal to 70% by coronary angiography or CT
             angiogram OR abnormal stress test (at least medium-sized, moderate reversible defect)
             OR a presence of a CAD risk equivalent as defined by the National Cholesterol
             Education Panel (NCEP)III as: Framingham risk score ≥ 20%, diabetes, or peripheral
             arterial disease(4)

          -  High Sensitivity C-reactive Protein (hs-CRP) ≥ 2.0 mg/L

          -  History of stage 3 or 4 chronic Kidney disease (CKD) defined as an glomerular
             filtration rate (eGRF) by the Modification of Diet in Renal Disease (MDRD) formula of
             15-60 mL/min/1.73 m2

          -  Low level of serum 25-hydroxyvitamin D (&lt;30ng/mL)

          -  Evidence of secondary hyperparathyroidism defined as intact parathyroid hormone (iPTH)
             level &gt; 70 pg/mL

          -  Stable dose of statin and/or other lipid lowering therapy (ie: ezetimibe, fibrates,
             bile acid sequestrants nicotinic acid, fish oil) for 12 weeks prior to enrollment
             without known plans for change to current therapy during the study period

        Exclusion Criteria:

          -  History of myocardial infarction, stroke, or cardiac surgery within 6 months of
             enrollment

          -  History of carotid artery surgery

          -  Planned cardiovascular surgery or procedure, with the exception of permanent pacemaker
             placement, in the next 18 months.

          -  Use of vitamin D or calcium supplementation within the past 12 weeks with the
             exception of calcium containing phosphate binders and a daily multivitamin containing
             ≤ 400 IU of vitamin D

          -  Hypercalcemia (as defined by the laboratory upper limit of normal ) or
             hyperphosphatemia (≥ 5.5 mg/dL)

          -  Plan to initiate renal replacement therapy (dialysis) during the study

          -  History of left ventricular systolic dysfunction with an ejection fraction &lt;50% or
             history of New York Heart Association (NYHA)functional Class II-IV congestive heart
             failure

          -  Uncontrolled blood pressure, defined as systolic blood pressure greater than 160 mmHg
             and diastolic blood pressure greater than 100 mm Hg at the screening visit

          -  Uncontrolled diabetes, defined as hemoglobin A1C ≥ 10.0

          -  History of any surgery within the past 3 months or known to be planned during the
             study period

          -  History of malignancy within the past 5 years with the exception of non-melanoma (ie:
             squamous cell or basal cell) skin cancer

          -  History of a known systemic or pulmonary inflammatory condition (including rheumatoid
             arthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease,
             pulmonary fibrosis, sarcoidosis, Wegener's granulomatosis, Goodpasture's disease)

          -  History of renal or other organ transplant and/or immunosuppressed state (ie
             immunosuppressive therapy or condition such as HIV)

          -  History of any other condition, that in the opinion of the investigators renders it
             unsafe for the subject to be enrolled

          -  For woman able to become pregnant, unwillingness to use birth control

          -  Participation in another clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David J Whellan, MD MHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2009</study_first_submitted>
  <study_first_submitted_qc>November 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2009</study_first_posted>
  <results_first_submitted>May 30, 2013</results_first_submitted>
  <results_first_submitted_qc>September 5, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 11, 2013</results_first_posted>
  <last_update_submitted>May 13, 2014</last_update_submitted>
  <last_update_submitted_qc>May 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <keyword>Coronary Artery Disease (CAD)</keyword>
  <keyword>Chronic Kidney Disease (CKD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
    <mesh_term>Avitaminosis</mesh_term>
    <mesh_term>Rickets</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The enrollment period began in November 2009. The first subject was emrolled June 17, 2010. The final subject (#12) was enrolled April 14, 2011.</recruitment_details>
      <pre_assignment_details>2 additional participants were in a washout period when the study was stopped. These participants were not enrolled or randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Participants</title>
          <description>The participants could have been randomized to one of the 2 arms; study drug or placebo. The study was never unblinded before termination.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">No subjects completed the study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Trial was stopped before completed</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Enrolled</title>
          <description>Total number participants consentedand enrolled</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in High Sensitivity-C Reactive Protein (Serum)</title>
        <time_frame>1 year</time_frame>
        <population>Data were not collected when study was stopped prematurely.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>no arm /group title is provided as there was no enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in High Sensitivity-C Reactive Protein (Serum)</title>
          <population>Data were not collected when study was stopped prematurely.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Markers of Inflammation Including Interleukin (IL)-1, IL-6, Tumor Necrosis Factor Alpha, Matrix Metalloproteinase (MMP) -9 and Serum Amyloid A</title>
        <time_frame>1 year</time_frame>
        <population>Data were not collected when study was stopped prematurely.</population>
        <group_list>
          <group group_id="O1">
            <title>Alll Participants</title>
            <description>no arm /group title is provided as there was no enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Markers of Inflammation Including Interleukin (IL)-1, IL-6, Tumor Necrosis Factor Alpha, Matrix Metalloproteinase (MMP) -9 and Serum Amyloid A</title>
          <population>Data were not collected when study was stopped prematurely.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect on Known Coronary Artery Disease Risk Factors Including Lipids and Blood Pressure.</title>
        <time_frame>1 year</time_frame>
        <population>Data were not collected when study was stopped prematurely.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>No arm/group title is provided</description>
          </group>
        </group_list>
        <measure>
          <title>Effect on Known Coronary Artery Disease Risk Factors Including Lipids and Blood Pressure.</title>
          <population>Data were not collected when study was stopped prematurely.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect on Carotid Intima-media Thickening (CIMT)</title>
        <time_frame>1 year</time_frame>
        <population>Data were not collected when study was stopped prematurely.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>No arm/group title is provided</description>
          </group>
        </group_list>
        <measure>
          <title>Effect on Carotid Intima-media Thickening (CIMT)</title>
          <population>Data were not collected when study was stopped prematurely.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>All Participants</title>
          <description>All participants in the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Muscles cramp, fever, hypotension,</sub_title>
                <description>Required intravenous fluid. Not attributable to study.</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Left rotator cuff surgery</sub_title>
                <description>Not attributed to study</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Cramping in left hand</sub_title>
                <description>Not attributable to study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>bilateral cataract surgery</sub_title>
                <description>Not attributable to study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination secondary to enrollment futility.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>David Whellan MD</name_or_title>
      <organization>Thomas Jefferson University</organization>
      <phone>215 955 5050</phone>
      <email>david.whellan@jefferson.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

